The vaccine is personalized to a patient's tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer.
Daraxonrasib targets RAS, a cancer-driving protein found in roughly 25% of human cancers and more than 90% of pancreatic cancers, long considered "undruggable." This isn't a cure, but it is a crack, an early sign of the undruggable becoming druggable.
5mo ago
Underscored — save the words that stop you in your tracks.
